Two controlled trials have tested EMTT for low back pain. In a 2017 trial of 87 people with chronic nonspecific low back pain, adding eight EMTT sessions to physiotherapy and pain medication reduced pain and disability more than physiotherapy and medication alone. In a 2026 double-blind trial, people with degenerative lower-spine pain had less pain with active EMTT than with sham. The evidence is encouraging but limited: two trials, short follow-up, and only one with a sham control.
Which low back pain does this apply to?
Both trials studied long-standing back pain without nerve-root involvement or red flags. One studied chronic nonspecific low back pain, the most common kind. The other studied lumbar spondyloarthrosis, meaning wear-related (arthritic) changes in the small joints of the lower spine.
The results should not be applied to:
- Sciatica or other nerve-root pain, where symptoms travel down the leg with numbness or weakness
- Spinal stenosis, fracture, infection, tumor or inflammatory spinal disease
- Progressive weakness or loss of bladder or bowel control, which needs urgent medical care
Leg-dominant nerve symptoms need a different assessment, covered on our sciatica and nerve entrapment page.
The 2017 trial: EMTT added to standard care
Krath and colleagues, in the Journal of Orthopaedics, randomized 87 people with chronic nonspecific low back pain. All received six weeks of physiotherapy and pain medication. Half (44) also received eight EMTT sessions.
| Measure | Standard care + EMTT | Standard care alone |
|---|---|---|
| Pain (0–10), start | 5.8 | 5.6 |
| Pain, 12 weeks after treatment | 2.1 (about 65% lower) | 3.0 (about 49% lower) |
| Oswestry disability score, start | 53 | 53 |
| Oswestry disability score, 12 weeks after treatment | 21 | 30 |
Both groups improved, and the EMTT group improved significantly more. Lower Oswestry scores mean less disability in daily activities.
The important limitation is that there was no sham treatment. The comparison group simply did not receive EMTT, so patients knew which group they were in. Some of the extra improvement could come from the added attention and expectation of an additional treatment rather than from EMTT itself.
The 2026 trial: EMTT against a sham
Hollander and colleagues, in the Journal of Back and Musculoskeletal Rehabilitation, ran a double-blind trial in 126 people with long-standing knee, shoulder or lower-spine pain. The largest group, 52 people, had lumbar spondyloarthrosis. Patients received eight weekly sessions of active EMTT or a sham treatment, and anti-inflammatory drugs were stopped during the study.
Across the whole trial, pain fell from about 5 to 2.2 with active EMTT and to 4.2 with sham at 12 weeks, and physical function improved more with EMTT. In the lower-spine group on its own, pain was lower with active EMTT than with sham at both 6 and 12 weeks. The trial was sized for the combined group rather than for each condition, so the back-pain result on its own is less certain than the overall result. We cover the trial in detail in EMTT on its own: what the largest placebo-controlled trial found.
What the two trials do and do not show
Together, they suggest EMTT can reduce pain in some people with long-standing low back pain, both alone and as an addition to standard care. They do not show:
- Lasting benefit. Neither trial followed patients beyond about three months after treatment.
- Structural change. Neither measured the discs, joints, muscles or fascia. There is no evidence that EMTT reverses spinal degeneration.
- Who benefits most. The trials were too small to identify which patients respond.
- A settled protocol. The 2026 trial used 80 mT, 8 Hz and 10,000 pulses once a week for eight weeks. The 2017 trial also used eight sessions. Other schedules have not been compared.
Settings matter. A 2026 systematic review of EMTT and pulsed electromagnetic field trials found that low-intensity protocols often did no better than placebo, while high-intensity protocols were more consistently associated with improvement. Results from these trials should not be assumed for low-intensity home devices.
How EMTT compares with shockwave for back pain
Shockwave has a larger evidence base in chronic low back pain, including several meta-analyses, which we review in shockwave therapy for chronic low back pain. No trial has compared EMTT with shockwave head to head in the low back. The two work differently: shockwave is a mechanical pressure pulse aimed at muscle and fascia, while EMTT is a magnetic field rather than a pressure pulse. Both are best thought of as additions to active rehabilitation, not replacements for it.
How we use this research
For long-standing low back pain, we start with an exam to sort out what appears to be involved: muscle and fascia, joint findings, load tolerance, and any nerve or red-flag signs. Exercise and graded activity remain central to most plans. EMTT, shockwave or both may be added when the findings fit, and we explain what results are realistic. If back pain has outlasted normal recovery, book a new patient exam or read more about our approach to chronic low back pain.
Sources
- Krath A, Klüter T, Stukenberg M, et al. Electromagnetic transduction therapy in non-specific low back pain: a prospective randomised controlled trial. Journal of Orthopaedics. 2017;14(3):410-415. PMID 28736490. (link)
- Hollander K, Burgkart R, von Eisenhart-Rothe R, Vester J, Gerdesmeyer L. Extracorporeal magnetotransduction therapy (EMTT) for management of musculoskeletal disorders: a double-blind, placebo-controlled, randomised trial. Journal of Back and Musculoskeletal Rehabilitation. 2026;39(3):885-895. PMID 41313312. (link)
- Leyva Martínez I, Ramírez Arteaga A, Martínez-Rojano H, et al. Contemporary advances (2015–2026) in extracorporeal electromagnetic transduction therapy and pulsed electromagnetic fields for musculoskeletal disorders: a systematic review of dosimetry and clinical response. Biomedicines. 2026;14(8):1731. PMID 42652114. (link)
